Introduction
============

It is evidenced that femtosecond laser-assisted in situ keratomileusis (LASIK) is an established, effective, and safe technique used to treat myopia and myopic astigmatism.[@b1-opth-10-1639]--[@b9-opth-10-1639] The creation of a flap thickness ranging from 100 to 130 μm with a standard deviation of 10--15 μm using femtosecond lasers is considered state of the art.[@b2-opth-10-1639],[@b3-opth-10-1639],[@b7-opth-10-1639] Femtosecond laser surgery offers a safety advantage over microkeratome-based LASIK procedures.[@b8-opth-10-1639]--[@b14-opth-10-1639] The accurate spot positioning, spacing, and optimized spatial and temporal scan sequences of the laser spot, as well as the possibility of having variation of flap width, flap depth, hinge width, variable diameter, and side-cut angles lead to better surgical results.[@b9-opth-10-1639]--[@b15-opth-10-1639]

Commercially available femtosecond lasers in refractive surgery are the IntraLase (Abbott Medical Optics Inc, Santa Ana, CA, USA), which was the first femtosecond laser introduced in the US in 2001;[@b11-opth-10-1639] the Technolas Femtosecond Workstation, formerly known as Femtec, by Technolas Perfect Vision (Munich, Germany); the FEMTO LDV by Ziemer Ophthalmic Systems (Port, Switzerland), introduced in the late 2005;[@b3-opth-10-1639] the Visumax by Carl Zeiss Meditec AG (Jena, Germany), introduced in the fall of 2006;[@b3-opth-10-1639] and the WaveLight FS200 (Alcon Laboratories, Inc., Fort Worth, TX, USA) that received US Food and Drug Administration approval in 2010.[@b5-opth-10-1639]

There are two different concepts in photodisruption process, either high pulse energy and low pulse frequency, such as IntraLase and Femtec, or low pulse energy and high pulse frequency, such as FEMTO LDV and WaveLight FS200.[@b3-opth-10-1639] Higher-energy lasers operate in the microjoule (μJ) range and repetition frequencies are in the kilohertz (kHz) range. In these systems, each laser spot creates an expansile bubble that facilitates the disruption process by allowing for a greater separation of laser pulses. On the other hand, the lower-energy lasers operate in the nanojoule range (nJ) and require closer spacing of the laser pulses and repetition frequencies are in the megahertz (MHz) range.[@b3-opth-10-1639] In both methods, the laser spots create a potential geometric shape or plane that is then manually dissected to complete the process.

IntraLase 60 kHz system is a very commonly used laser of high pulse energy and low pulse frequency, with a wavelength of 1,053 nm.[@b3-opth-10-1639] WaveLight FS200 femtosecond laser system is a low-energy and high pulse frequency laser that emits laser pulses with duration of 350 fs at a wavelength of 1,050 nm and pulse repetition rate of 200 kHz.[@b7-opth-10-1639] IntraLase 60 kHz system uses a flat contact surface, while WaveLight FS200 uses a curved contact surface.[@b3-opth-10-1639],[@b7-opth-10-1639]

The main purpose of this study was to compare the safety, efficacy, and predictability of femtosecond LASIK performed by two different laser suites.

Materials and methods
=====================

This retrospective, nonrandomized two-site study analyzed data of 28 patients with myopia who had undergone bilateral femtosecond LASIK. Patients were divided into two groups. Each group consisted of 14 patients (28 eyes). The first group had undergone femtosecond LASIK using IntraLase FS 60 femtosecond and the Visx Star S4 IR Excimer laser (Abbott Medical Optics Inc). The second group had undergone femtosecond LASIK using the WaveLight FS200 femtosecond and the EX500 Excimer laser (Alcon Laboratories, Inc.). Patients from the first group received a wavefront-guided (WFG) LASIK and the ones from the second group received a wavefront-optimized (WFO) LASIK. The latter were matched with patients selected in the first group based on age, sex, and preoperative mean refractive spherical equivalent (MRSE). The same surgeon (AM) performed all surgeries in both groups.

Patients included in the study were 18 years or older, had stable refraction, corrected distance visual acuity (CDVA) of 20/25 or better for each eye, no contraindications for LASIK, no history of previous ocular surgery, preoperative central corneal thickness \>500 μm, and a minimum residual thickness of 280 μm with at least a 110 μm femtosecond laser-assisted flap, based on calculation simulation, and were able to return for follow-up on certain days and in certain months. In all eyes, the intended corneal flap thickness was 110±5 μm. In eyes treated with the IntraLase FS 60 system, 8.4--8.9 mm diameter flaps were created. All flaps had superior hinges with side-cut angles of 70° and hinge angles of 50°. The bed laser pulse energy was 1.0 μJ. The bed separation, and spot and line separations were 7 μm. In eyes treated with the WaveLight FS200, all flaps had superior hinges with side-cut angles of 70° and hinge angles of 50°. The bed laser pulse energy was 0.69 μJ. The bed separation, as well as spot and line separations were 7 μm.

Preoperative mean spherical equivalent (SE) was between −1.50 and −8.5 D and astigmatism was up to 1.75 D. All patients had standard preoperative evaluation, which included uncorrected distance visual acuity (UDVA), CDVA, manifest refraction, intraocular pressure, slit lamp examination, keratometry, corneal topography (Orbscan II2; Bausch & Lomb Incorporated, Bridgewater, NJ, USA), wavefront aberrometry (Wavescan, Abbott Medical Optics Inc), tear function assessment, and dilated fundus examination. Patients were evaluated postoperatively at 1-day, 1-week, 1-month, and 6-month follow-up. Postoperatively, all patients were prescribed moxifloxacin hydrochloride 0.5% eyedrops (Vigamox, Alcon Laboratories, Inc.) and dexamethasone 0.1% eyedrops (Maxidex, Alcon Laboratories, Inc.) four times a day for 1 week. The study was approved by the ethics committees of the Hyper-vision Laser Centre and the Eye Day Clinic, Athens, Greece and followed the principles of the Declaration of Helsinki. Written informed consent was obtained from the patients.

Statistical analysis
--------------------

Statistical analyses were conducted using Statistical Package for the Social Sciences statistical software (version 18.0; SPSS Inc., Chicago, IL, USA). Continuous variables are presented as mean and standard deviation. Quantitative variables are presented as absolute and relative frequencies. For the comparison of proportions, chi-square and Fisher's exact tests were used. For comparing the study variables between the two groups, the nonparametric Mann--Whitney test was used for non-normal variables and Student's *t*-test for normal variables. The main refractive measures included safety (safety index: mean postoperative CDVA divided by mean preoperative CDVA), efficacy (efficacy index: mean postoperative UDVA divided by mean preoperative CDVA), and predictability, (target SE within ±0.5 D of attempted correction). Differences in changes of UDVA, CDVA, and MRSE during the follow-up period between the two study groups were evaluated using repeated measures analysis of variance. The ranks in analysis of variance were used for MRSE due to their skewed distribution. All *P*-values reported are two-tailed. Statistical significance was set at 0.05.

Results
=======

A total of 56 eyes (28 patients) were included in the study. The mean age of patients was 34±8.3 years in group 1 (42.9% males) and 31.8±9.3 years in group 2 (50.0% males). Characteristics of the two study groups are presented in [Table 1](#t1-opth-10-1639){ref-type="table"}. Preoperative MRSE was −3.76±1.67 D in the first group and −4.57±2.2 D in the second group (*P*=0.206). There was no statistically significant difference in any baseline characteristic of patients in the two study groups.

Efficacy
--------

At the 6-month follow-up, there was no significant difference in UDVA (decimal) between the two suites (*P*=0.285) ([Table 2](#t2-opth-10-1639){ref-type="table"}). Also, 78.6% of eyes in group 1 and 92.9% of eyes in group 2 achieved UDVA of 20/20 or better (*P*=0.252) ([Figure 1A and B](#f1-opth-10-1639){ref-type="fig"}; [Table 3](#t3-opth-10-1639){ref-type="table"}). Twenty-eight point six percent of eyes achieved UDVA of 20/16 or better in a week post-operatively in group 2 versus 21.4% in group 1 (*P*=0.758). Thirty-two point one percent of eyes achieved UDVA of 20/16 or better in 1 month postoperatively in group 2 versus 25% in group 1 (*P*=0.768). One eye in group 1 had microstriae with astigmatism resulting in UDVA of 20/30 and one patient had transient light sensitivity syndrome in group 1, which lasted for 5 weeks after surgery and regressed with intensive topical corticosteroids.

Safety and complications
------------------------

None of the patients of both groups lost lines of CDVA at the 6 months follow-up. Thirty-five point seven percent and 50% in group 1 and group 2, respectively, gained one line (*P*=0.179) ([Figure 1C](#f1-opth-10-1639){ref-type="fig"}). Thirty-nine point three percent of eyes in the first group and 35.7% in the second group were unchanged ([Figure 1C](#f1-opth-10-1639){ref-type="fig"}). There were no intraoperative complications related to femtosecond laser-assisted LASIK flap creation.

Predictability
--------------

MRSE at 6 months follow-up was 0.05±0.26 in group 1 and 0.07±0.24 in group 2 (*P*=0.495) ([Table 4](#t4-opth-10-1639){ref-type="table"}). Twenty-five eyes in group 1 (92.7%) and 27 eyes in group 2 (96.3%) had MRSE within ±0.5 D at 6 months (*P*\>0.999) ([Figures 1D, E](#f1-opth-10-1639){ref-type="fig"} and [2A](#f2-opth-10-1639){ref-type="fig"}). One eye in group 1 displayed change in MRSE of \>0.5 D from 1 to 6 months postop, whereas no eye presented any change in group 2.

Refractive astigmatism
----------------------

The postoperative astigmatism at 1- and 6-month follow-up was similar between the two groups (*P*\>0.05) ([Table 5](#t5-opth-10-1639){ref-type="table"}) ([Figure 2B and C](#f2-opth-10-1639){ref-type="fig"}). Regarding stability, refractive outcomes were stable at 6 months postoperatively ([Figure 2D and E](#f2-opth-10-1639){ref-type="fig"}).

Discussion
==========

This study evaluated the visual outcomes of 56 eyes that were treated with two different femtosecond laser suites. To our knowledge, no other study has compared the above refractive suites in terms of efficacy, safety, and predictability.

At 6-month follow-up, 92.8% of eyes in group 2 and 78.6% of eyes in group 1 achieved a UDVA of 20/20 or better. No eye lost lines of CDVA. The mean efficacy index at 6 months was 1.10±0.12 in group 1 and 1.10±0.1 in group 2 (*P*=0.799). The mean safety index at 6-month follow-up was 1.10±0.10 in group 1 and 1.10±0.09 in group 2 (*P*=0.407).

In a previous study,[@b16-opth-10-1639],[@b17-opth-10-1639] both IntraLase 60 kHz and Visumax 500 kHz produced comparable efficacy and predictability profiles for flap creation in LASIK. In another study by Yu and Manche,[@b18-opth-10-1639] when comparing the 150 kHz femtosecond group versus the 60 kHz group, 94.5% and 85.2% of eyes, respectively, achieved a UDVA of 20/20 or better in 6-month follow-up. However, in that study, the 60 kHz and the 150 kHz femtosecond systems showed similar predictability 12 months postoperatively. Also, in the same study, the FS200 femtosecond group had a better UDVA faster, which, according to the authors, is suggestive of a faster visual recovery. However, when using Bonferroni correction, the authors concluded that the difference in 1 week was not statistically significant. The authors suggest that a faster flap creation time leads to reduction in stromal cell damage and smoother flap interface allowing for more rapid healing.

In this study, the percentage of eyes that achieved UDVA of 20/16 or better in a month postoperatively in group 2 was greater than the percentage obtained in group 1. This is suggestive of a faster recovery in group 2, despite the fact that the difference in 1 week was not statistically significant in either group. Kymionis et al[@b15-opth-10-1639] found the IntraLase 150 kHz femtosecond laser to be comparable to the WaveLight FS200 system. We suggest that higher-energy lasers create smoother interface and less corneal damage, which means faster recovery. Therefore, our results are similar to those of previous studies that compared higher-energy lasers to lower-energy ones.

A recent meta-analysis[@b9-opth-10-1639] that compared different types of FS lasers for LASIK showed that there is no statistically significant difference in the loss of ≥2 Snellen lines of CDVA (safety) between different FS lasers and no statistically significant difference in the mean spherical equivalent within ±0.5 D of target refraction (predictability). However, IntraLase and FEMTO LDV were significantly better in the proportion of eyes within a UDVA of 20/20 or better (efficacy). Also, IntraLase and WaveLight SF200 had the least intraoperative complications, with the most frequently reported being diffuse lamellar keratitis and microstriae. IntraLase FS 60 kHz, Visumax, and WaveLight FS200 seldom had postoperative complications such as loss of suction, transient opaque bubble layer, and adhesions.

In this study, we had neither free flaps, irregular flaps, decentered flaps, and epithelial defects, nor complications[@b19-opth-10-1639] such as opaque bubble layer.[@b20-opth-10-1639] In the IntraLase group, we had only one patient with transient light sensitivity syndrome[@b21-opth-10-1639],[@b22-opth-10-1639] and an eye with microstriae. It is well known that if microstriae involve the visual axis, they can induce irregular astigmatism and decrease the CDVA. In our study, we had an eye with microstriae that induced astigmatism and decreased CDVA, which was treated by lifting the flap, hydrating, stretching, repositioning, and swelling it with hypotonic solutions. However, the above patients were among the first cases before making proper adjustments to the laser platform.

We used different ablation systems, the WFG and the WFO treatments. Previous studies[@b23-opth-10-1639]--[@b25-opth-10-1639] that compared the visual outcomes of WFG versus WFO have evaluated the efficacy, safety, and predictability of both treatments, although Allegretto Wave Eye-Q 400 Hz was used instead of EX500 Excimer laser. In the study by He et al,[@b23-opth-10-1639] on comparing the clinical outcomes of WFG LASIK versus WFO treatment, both treatments were able to correct myopia safely and effectively. However, WFG treatment offered significant advantages in terms of residual refractive error, uncorrected distance acuity, and contrast sensitivity. In another study,[@b25-opth-10-1639] when comparing the visual outcomes of variable spot scanning ablation versus WFO using the same excimer lasers, both treatments were able to correct myopia safely and effectively and the same visual performance of eyes was recorded in either group. Finally, in another study,[@b24-opth-10-1639] WFG and WFO LASIK produced similar results in myopic patients. However, the WFG approach yielded gains in visual acuity, predictability, and high order aberrations.

In this study, both techniques showed comparative accuracy, predictability, safety, and stability. However, better UDVA in a month postoperatively in group 2 could be attributed to the faster ablation of the WaveLight EX500; being a fast laser, it has great advantage compared to Visx, enabling treatments of each diopter of myopia in 1.4 seconds (based on a 6.0 mm optical zone of treatment). Therefore, it may produce better visual outcomes by reducing stromal dehydration, flap shrinkage, sensitivity to eye movements, and patient fixation fatigue.[@b26-opth-10-1639]

Yet, there are certain limitations to this study. It is a retrospective, not a randomized eye-to-eye study. Changes in aberrations and contrast sensitivity are not reported. Besides, this study had a small sample size and a 6-month follow-up period. Therefore, we need larger studies with longer-term follow-up to detect discreet differences between the two laser suites.

In summary, in this study, the refractive and visual outcomes were similar between the two laser suites. Despite the shorter pulse duration, lower energy setting of the FS200 system, and the faster ablation of the Wavelight EX500 excimer laser, at a 6-month follow-up, there were no remarkable differences in efficacy, safety, and predictability between both groups. We suggest that WFG treatment may improve the final visual outcomes of group 1, as according to most studies,[@b24-opth-10-1639],[@b26-opth-10-1639]--[@b29-opth-10-1639] this treatment is slightly superior in terms of refractive outcomes, minimizing the induction of high order aberrations and improving contrast sensitivity. In the end, both laser suites resulted in excellent outcomes.
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![Efficacy and safety outcomes at 6 months (56 eyes).\
**Notes:** Six-month postoperative (56 eyes) cumulative UDVA, group 1 (**A**); 6-month postoperative cumulative UDVA, group 2 (**B**); change in corrected distance visual acuity in both groups (**C**); attempted versus achieved SE in group 1 (**D**) and in group 2 (**E**). Group 1: FS 60 kHz + Visx Star S4 IR (Abbott, Medical Optics, Inc., Santa Ana, CA, USA); Group 2: WaveLight FS200 (Alcon Laboratories, Inc., Fort Worth, TX, USA) + WaveLight EX500 (Alcon Laboratories, Inc.).\
**Abbreviations:** CDVA, corrected distance visual acuity; SE, spherical equivalent; UDVA, uncorrected distance visual acuity; postop, postoperative.](opth-10-1639Fig1){#f1-opth-10-1639}

![Predictability and stability at 6 months.\
**Notes:** Six-month refractive accuracy (56 eyes) in both groups (**A**), refractive astigmatism in group 1 (**B**) and in group 2 (**C**), refractive stability in group 1 (**D**) and in group 2 (**E**). Group 1: FS 60 kHz + Visx Star S4 IR (Abbott, Medical Optics, Inc., Santa Ana, CA, USA); Group 2: WaveLight FS200 (Alcon Laboratories, Inc., Fort Worth, TX, USA) + WaveLight EX500 (Alcon Laboratories, Inc.).\
**Abbreviations:** preop, preoperative; postop, postoperative.](opth-10-1639Fig2){#f2-opth-10-1639}

###### 

Characteristics of the two study groups

                     Group 1        Group 2        *P*-value
  ------------------ -------------- -------------- ---------------------------------------------------
  Sex, male, n (%)   6 (42.9)       7 (50.0)       0.705[a](#tfn1-opth-10-1639){ref-type="table-fn"}
  Age (years)        34.0 (8.3)     31.8 (9.3)     0.511[b](#tfn2-opth-10-1639){ref-type="table-fn"}
  K (D)              43.8 (1.3)     43.3 (1.6)     0.193[b](#tfn2-opth-10-1639){ref-type="table-fn"}
  CCT (μm)           558.9 (37.6)   541.4 (58.8)   0.092[b](#tfn2-opth-10-1639){ref-type="table-fn"}

**Notes:**

Fisher's exact test;

Student's *t*-test. Group 1: FS 60 kHz + Visx Star S4 IR (Abbott, Medical Optics, Inc., Santa Ana, CA, USA); Group 2: WaveLight FS200 (Alcon Laboratories, Inc., Fort Worth, TX, USA) + WaveLight EX500 (Alcon Laboratories, Inc.).

**Abbreviations:** CCT, corneal thickness; K, keratometry; SD, standard deviation.

###### 

Comparison of efficacy between the two study groups

  Group                                                   UDVA 1 week (decimal)   UDVA 1 month (decimal)   UDVA 6 months (decimal)   *P*-value[a](#tfn4-opth-10-1639){ref-type="table-fn"} 1 week versus 6 months   *P*-value[b](#tfn5-opth-10-1639){ref-type="table-fn"}                  
  ------------------------------------------------------- ----------------------- ------------------------ ------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------- ------ ------- -------
  Group 1                                                 1.00                    0.15                     1.01                      0.15                                                                           1.06                                                    0.15   0.001   0.285
  Group 2                                                 1.04                    0.12                     1.04                      0.12                                                                           1.08                                                    0.13   0.008   
  *P*-value[c](#tfn6-opth-10-1639){ref-type="table-fn"}   0.304                                            0.293                                                                                                    0.602                                                                  

**Notes:**

*P*-value for time effect;

effects reported include differences between the two groups in the degree of change in the particular variable (repeated measurements ANOVA);

*P*-value for group effect. Group 1: FS 60 kHz + Visx Star S4 IR (Abbott, Medical Optics, Inc., Santa Ana, CA, USA); Group 2: WaveLight FS200 (Alcon Laboratories, Inc., Fort Worth, TX, USA) + WaveLight EX500 (Alcon Laboratories, Inc.).

**Abbreviations:** ANOVA, analysis of variance; SD, standard deviation; UDVA, uncorrected distance visual acuity.

###### 

Efficacy comparison of the two study groups

  Parameter             Group 1   Group 2   *P*-value[a](#tfn8-opth-10-1639){ref-type="table-fn"}
  --------------------- --------- --------- -------------------------------------------------------
  **Efficacy (UDVA)**                       
  1 week                                    
   20/16 or better      21.4      28.6      0.758
   20/20 or better      78.6      92.9      0.252
  1 month                                   
   20/16 or better      25.0      32.1      0.768
   20/20 or better      78.6      92.9      0.252
  6 months                                  
   20/16 or better      46.4      46.4      \>0.999

**Notes:**

Pearson chi-square test. Group 1: FS 60 kHz + Visx Star S4 IR (Abbott, Medical Optics, Inc., Santa Ana, CA, USA); Group 2: WaveLight FS200 (Alcon Laboratories, Inc., Fort Worth, TX, USA) + WaveLight EX500 (Alcon Laboratories, Inc.).

**Abbreviation:** UDVA, uncorrected distance visual acuity.

###### 

Mean MRSE values at baseline and during follow-up for both study groups

  Group                                                    MRSE at baseline   MRSE at 1 month follow-up   MRSE at 6 months follow-up   *P*-value[a](#tfn10-opth-10-1639){ref-type="table-fn"}   *P*-value[b](#tfn11-opth-10-1639){ref-type="table-fn"}                    
  -------------------------------------------------------- ------------------ --------------------------- ---------------------------- -------------------------------------------------------- -------------------------------------------------------- ------ --------- -------
  Group 1                                                  −3.76              1.67                        0.09                         0.32                                                     0.05                                                     0.26   \<0.001   0.132
  Group 2                                                  −4.57              2.2                         0.13                         0.26                                                     0.07                                                     0.24   \<0.001   
  *P*-value[c](#tfn12-opth-10-1639){ref-type="table-fn"}   0.206                                          0.802                                                                                 0.495                                                                     

**Notes:**

*P*-value for change from baseline to 6 months;

effects reported include differences between the two groups in the degree of change in the particular variable (repeated measurements ANOVA);

*P*-value for group effect. Group 1: FS 60 kHz + Visx Star S4 IR (Abbott, Medical Optics, Inc., Santa Ana, CA, USA); Group 2: WaveLight FS200 (Alcon Laboratories, Inc., Fort Worth, TX, USA) + WaveLight EX500 (Alcon Laboratories, Inc.).

**Abbreviations:** ANOVA, analysis of variance; MRSE, mean refractive spherical equivalent; SD, standard deviation.

###### 

Postoperative astigmatism at 1 and 6 months for the two study groups

                                          Group 1   Group 2   *P*-value[a](#tfn14-opth-10-1639){ref-type="table-fn"}          
  --------------------------------------- --------- --------- -------------------------------------------------------- ------ ---------
  Postoperative astigmatism at 1 month                                                                                        
   ≤0.25                                  17        60.7      16                                                       57.1   \>0.999
   0.26--0.5                              10        35.7      11                                                       39.3   
   0.51--0.75                             1         3.6       1                                                        3.6    
  Postoperative astigmatism at 6 months                                                                                       
   ≤0.25                                  23        82.1      26                                                       92.9   0.422
   0.26--0.5                              4         14.3      2                                                        7.1    
   0.51--0.75                             1         3.6       0                                                        0      

**Notes:**

Fisher's exact test. Group 1: FS 60 kHz + Visx Star S4 IR (Abbott, Medical Optics, Inc., Santa Ana, CA, USA); Group 2: WaveLight FS200 (Alcon Laboratories, Inc., Fort Worth, TX, USA) + WaveLight EX500 (Alcon Laboratories, Inc.).
